156130-41-5

Basic information

• Product Name: (alphaS,3R,4R)-4-(3-Hydroxyphenyl)-3,4-dimethyl-alpha-(phenylmethyl)-1-piperidinepropanoic acid
• Synonyms: (alphaS,3R,4R)-4-(3-Hydroxyphenyl)-3,4-dimethyl-alpha-(phenylmethyl)-1-piperidinepropanoic acid;(R)-2-Benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanoic acid;(αS,3R,4R)-4-(3-Hydroxyphenyl)-3,4-diMethyl-α-(phenylMethyl)-1-piperidinepropanoic Acid;[3R-[1(S*),3α,4α]]-4-(3-Hydroxyphenyl)-3,4-diMethyl-α-(phenylMethyl)-1- piperidinepropanoic Acid;ADL 08-0011;(S)-2-benzyl-3-[(3R,4R)-4-(3-Hydroxyphenyl)-3,4-diMethylpiperidin-1-yl]propanoic acid;AlviMopan Metabolite (ADL 08-0011);AlviMopan AMide Hydrolyzed Metabolite
• CAS NO: 156130-41-5
• Molecular Formula: C₂₃H₂₉NO₃
• Molecular Weight: 367
• EINECS: 1312995-182-4
• Mol File: 156130-41-5.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 552.5±50.0 °C(Predicted)
• Appearance: /
• Density: 1.131
• Storage Temp.: 2-8°C
• PKA: 3.78±0.10(Predicted)
• CAS DataBase Reference: (alphaS,3R,4R)-4-(3-Hydroxyphenyl)-3,4-dimethyl-alpha-(phenylmethyl)-1-piperidinepropanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (alphaS,3R,4R)-4-(3-Hydroxyphenyl)-3,4-dimethyl-alpha-(phenylmethyl)-1-piperidinepropanoic acid(156130-41-5)
• EPA Substance Registry System: (alphaS,3R,4R)-4-(3-Hydroxyphenyl)-3,4-dimethyl-alpha-(phenylmethyl)-1-piperidinepropanoic acid(156130-41-5)

Safety Data

• Hazardous Substances Data: 156130-41-5(Hazardous Substances Data)

Usage

Uses

ADL 08-0011 is a metabolite of Alvimopan (A575800). Alvimopan amide hydrolized metabolite.

Upstream product

• 149541-62-8 C₁₉H₂₉NO₄ 
• 149541-62-8 cis-(-)-carbonic acid ethyl 1,3-dimethyl-4-[3-(l-methylethoxy)phenyl]-4-piperidinyl ester 
• 145340-44-9 1,3-dimethyl-4-[3-(propan-2-yloxy)phenyl]-4-piperidinol 
• 170098-29-0 methyl (αS,3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-α-(phenylmethyl)-1-piperidinepropanoate 
• 4629-80-5 1,3-dimethyl-4-piperidinone 
• 170098-39-2 methyl (3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinepropanoate 
• 145678-86-0 (3R,4R)-3,4-dimethyl-4-<3-(1-methylethoxy)phenyl>piperidinecarboxylic acid phenyl ester 
• 131738-73-3 3-(isopropyloxy)phenylbromide 
• 1184775-81-2 C₁₇H₂₇NO*C₂₀H₁₈O₈ 
• 143919-34-0 (3R,5R)-1,3,4-trimethyl-4-<3-(1-methylethoxy)phenyl>piperidine 
• 143919-32-8 (R)-1,2,3,4-tetrahydro-1,3-dimethyl-4-<3-(1-methylethoxy)phenyl>pyridine 
• 20593-63-9 2-Benzylacrylic acid ethyl ester 
• 119193-19-0 3-[(3R,4R)-3,4-dimethylpiperidin-4-yl]phenol 

Downstream Products

• 156053-89-3 Entereg 
• 145603-86-7 (+)-<<2'(S)-<<4(R)-3-(hydroxyphenyl)-3(R),4-dimethyl-1-piperidinyl>methyl>-1-oxo-3-phenylpropyl>amino>acetic acid 2-methylpropyl ester 
• 1257642-48-0 (S)-tert-butyl 2-benzyl-3-((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl)propanoate 
• 808101-37-3 C₃₃H₄₀N₂O₄ 
• 762300-05-0 C₂₉H₄₀N₂O₄ 

Relevant articles and documents

Synthesis and characterization of all possible diastereoisomers of alvimopan

Isolation of all possible diastereomers of alvimopan 1 was found to be challenging. In order to perform cut off studies during analytical method development, it was mandatory to synthesize and characterize all the diastereomeric impurities. Here in, our efforts toward the synthesis and isolation of alvimopan (1) diastereomers are discussed.

PROCESSES FOR THE PREPARATION OF PERIPHERAL OPIOID ANTAGONIST COMPOUNDS AND INTERMEDIATES THERETO

Novel processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto. The compounds prepared by the present processes may be useful, for example, as antagonists to the mu, kappa and delta opioid receptors, and thereby may be useful in the treatment of gastrointestinal motility disorders, and in preventing peripheral opiate induced side effects. The present processes may offer improved yields, chemical or stereochemical purity, ease of preparation and/or isolation of intermediates and final product, and more industrially useful reaction conditions and workability.

Compositions containing opioid antagonists

Compositions containing opioid antagonists are disclosed, particularly alvimopan and its active metabolite in solid dosage forms, where the drug is uniformly distributed, achieves the desired bioavailability, and is stable. Methods of preparing and using the compositions containing opioid antagonists are also disclosed. The results are achieved by a combination of processing techniques and component selection.